2-HOBA ingredient, called Hobamine, receives NPN from Health Canada
The 2-HOBA ingredient, Hobamine, was recently issued a NPN by Health Canada and may help with protecting and fighting against oxidative damage caused by free radicals.
Image | adobe.stock/shurkin_son
A recent press release disclosed that TSI Group’s Hobamine received a Natural Product Number (NPN) from Health Canada. The item’s number is #80138909 and according to the company, is also the first-ever to be issued for a 2-HOBA ingredient. By receiving an NPN, it shows that the ingredient has received Natural and Non-Prescription Health Products Directorate (NNHPD) approval.
“Receiving an NPN from Health Canada is a tremendous milestone for Hobamine, and a testament to TSI Group’s commitment to innovation in health and wellness,” said Shawn Baier, MS, MBA, TSI Group's vice president of business development. “This approval marks the first time Hobamine has been recognized in Canada, opening the door for consumers to experience its unique benefits.”
Hobamine is a form of the naturally-occurring compound 2-HOBA, and has the potential of protecting cells from fighting against oxidative damage caused by free radicals. According to the company's press release, the supplement works by “‘capturing’ common downstream products of oxidative stress that are linked to dysfunction.” Through this mechanism, Hobamine stops these downstream products from attaching to other cellular components.
“With regulatory validation, we can now work with partners to bring this breakthrough ingredient to Canadian consumers looking for next-generation health solutions," concluded Baier.
HHS announces restructuring plans to consolidate divisions and downsize workforce
Published: March 27th 2025 | Updated: March 27th 2025According to the announcement, the restructuring will save taxpayers $1.8 billion per year by reducing the workforce by 10,000 full-time employees and consolidating the department’s 28 divisions into 15 new divisions.
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
